Invicro Launches AmyloidIQ to Advance Clinical Imaging Trials in Alzheimer’s Disease

BOSTON, MA, March 19, 2018 – Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, recently announced the launch of AmyloidIQ, a new and advanced algorithm that quantifies Amyloid scans for use in subject stratification and clinical trials of Alzheimer’s disease therapies.

This novel algorithm calculates a single measure of the brain’s amyloid level denoted amyloid load, offering increased efficiencies within clinical imaging trials.  The new method encodes expert domain knowledge into an artificial intelligence algorithm that can accurately calculate the level of amyloid plaques in the brain. Test data from the Alzheimer’s Disease Neuroimaging Initiative database containing over 900 [18F] Florbetapir scans were analyzed with the new method and resulted in a 50% increase in power over other existing methods.   This technique opens the possibility of detecting smaller changes sooner, allowing clinical trials to run more efficiently and cost effectively by using reduced-size trials while achieving the same results.

Co-inventor and EVP of Quantitative Data Sciences for Invicro, Professor Roger Gunn, states, “By encoding expert domain knowledge into a computer algorithm for image analysis of amyloid scans we can increase power, reducing cost and timelines for clinical trials of novel AD therapeutics. This provides more powerful tools to Pharmaceutical Companies working in this important and challenging area.”

Professor Gunn collaborated with Dr. Alexander Whittington to develop and launch this innovative technique, which was presented and well received at the 12th Annual Human Amyloid Imaging Conference (HAI) in Miami, Florida. HAI 2018 provides an opportunity for academia and industry to share cutting edge advances in understanding amyloid pathology and its measurement in neurodegenerative disease.

For more information about AmyloidIQ or the use of amyloid Load analytics capabilities in clinical imaging trials, please contact and an Invicro specialist will be in touch.

About Invicro

Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017.  Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant®® and iPACS®, has inspired a strong and growing presence in the market.  For more information, visit

About Konica Minolta

Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit:


Media Contact:

Amanda Harrell

VP, Global Marketing